Risedronate sodium and Joint lock - a phase IV clinical study of FDA data

Summary:

Joint lock is reported as a side effect among people who take Risedronate sodium (risedronate sodium), especially for people who are male, 50-59 old, also take Enbrel, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Joint lock when taking Risedronate sodium. It is created by eHealthMe based on reports of 13,932 people who have side effects when taking Risedronate sodium from the FDA, and is updated regularly.

What is Risedronate sodium?

Risedronate sodium has active ingredients of risedronate sodium. It is often used in osteoporosis. eHealthMe is studying from 14,019 Risedronate sodium users. Check the latest studies of Risedronate sodium.

What is Joint lock?

Joint lock is found to be associated with 299 drugs and 493 conditions by eHealthMe. Check the latest studies of Joint lock.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

13,932 people reported to have side effects when taking Risedronate sodium.
Among them, 17 people (0.12%) have Joint lock.

Could Risedronate sodium cause Joint lock?

Among these 17 people:

What is the gender of people who have Joint lock when taking Risedronate sodium? *

female: 8.33 %
male: 91.67 %

What is the age of people who have Joint lock when taking Risedronate sodium? *

What are other drugs people take besides Risedronate sodium? *

What are other side effects people have besides Joint lock? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 17 people, 100.00%
Pain: 17 people, 100.00%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 17 people, 100.00%
Mobility Decreased (ability to move is reduced): 16 people, 94.12%
Drug Ineffective: 16 people, 94.12%
Insomnia (sleeplessness): 16 people, 94.12%
Joint Swelling: 16 people, 94.12%
Limb Discomfort (discomfort in leg): 16 people, 94.12%
Dyspnea (difficult or laboured breathing): 16 people, 94.12%
Tumor: 16 people, 94.12%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 17 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Risedronate sodium and have Joint lock?

- Check whether Joint lock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Risedronate sodium:

Risedronate sodium (14,019 reports)

Joint lock treatments and more:

Joint lock (3,416 reports)

Browse all side effects of Risedronate sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint lock:

Joint lock (299 drugs)

Browse all the conditions that are associated with Joint lock:

Joint lock (493 conditions)

Related publications that referenced our studies

Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on risedronate sodium (the active ingredients of Risedronate sodium) and Risedronate sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.